Clinical Trial Update: A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety [Phase 2]

View source ↗

Summary

A Phase 2 mechanistic study to assess a single dose of CYB003 in participants with depression and anxiety, currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Major Depressive Disorder

Drugs mentioned

• CYB003 (deuterated psilocin analog)

Snippet

Sponsor: Ohio State University | Conditions: Depression, Anxiety | Phase 2 | Status: NOT_YET_RECRUITING